Poorer Outcomes for Malignancy Patients with Diabetes

Patients with a co-diagnosis of malignancy and diabetes may have worse outcomes compared to malignancy patients without a diabetes diagnosis, a report observed. In this study, published in Diabetic Medicine, researchers analyzed single-center emergency department (ED) and hospital discharge data spanning Jan. 1, 2015, through Dec. 31, 2017. Patients with a diagnosis of malignancy and diabetes were identified. The study authors employed multivariate Cox regression models to determine the association between diabetes and all-cause mortality. The association between diabetes and length of hospital stay (LOS) was determined using a truncated negative binomial regression model. The impact of diabetes on number of ED re-presentations and readmissions was measured using Prentice–Williams–Peterson total time models. A total of 7,004 patients with malignancies were identified, of whom 1,195 (17.1%) also received a diabetes diagnosis. Malignancy patients with a diagnosis of diabetes had a greater number of inpatient readmissions (adjusted hazard ratio [aOR] 1.13; 95% CI, 1.03–1.24) and ED re-presentations (aOR 1.13; 95% CI, 1.05–1.22), and longer LOS (adjusted incidence rate ratio 1.14; 95% CI, 1.04–1.25). Patients with malignancy and diabetes had a 48% increased risk of all-cause mortality (aOR 1.48; 95% CI, 1.22–1.76). The researchers concluded, “People with malignancies and diabetes had significantly more emergency department presentations, more inpatient admissions, longer length of hospital stay and higher rates of all‐cause mortality compared to people with a malignancy without diabetes.”